The Use of Sandostatin® in Insulinomas. The Relation Between In Vivo Responses, the Presence of Somatostatin Receptors and the Development of Tachyphylaxis
作者： S. W. J. Lamberts , J.-C. Reubi
DOI: 10.1007/978-3-642-61328-9_5
关键词:
摘要: Patients with insulin-secreting islet cell tumors are at risk for severe, protracted hypoglycemia. Surgical removal of the tumor is treatment choice. During diagnostic work up, medical hypoglycemia often mandatory, while adequate protection against during operation sometimes difficult to achieve. In cases malignant (metastatic) insulinomas, curative surgery is, in most instances, not possible, necessitating additional (medical) therapy protect these patients from damage caused by hypoglycemic attacks.
springer.com
sci-hub.st 参考文章(11)
S. W.J. Lamberts, G. F. F. M. Pieters, H.J. Metselaar, G. L. Ong, H. S. Tan, J.-C. Reubi, Development of resistance to a long-acting somatostatin analogue during treatment of two patients with metastatic endocrine pancreatic tumours European Journal of Endocrinology. ,vol. 119, pp. 561- 566 ,(1988) , 10.1530/ACTA.0.1190561
Mara Lorenzi, John E. Gerich, John H. Karam, Peter H. Forsham, Failure of somatostatin to inhibit tolbutamide-induced insulin secretion in patients with insulinomas: a possible diagnostic tool. The Journal of Clinical Endocrinology and Metabolism. ,vol. 40, pp. 1121- 1124 ,(1975) , 10.1210/JCEM-40-6-1121
JEAN-CLAUDE REUBI, JEAN RIVIER, MARILYN PERRIN, MARVIN BROWN, WYLIE VALE, Specific high affinity binding sites for somatostatin-28 on pancreatic beta-cells: differences with brain somatostatin receptors. Endocrinology. ,vol. 110, pp. 1049- 1051 ,(1982) , 10.1210/ENDO-110-3-1049
J. C. REUBI, W. H. HÄCKI, S. W. J. LAMBERTS, Hormone-producing gastrointestinal tumors contain a high density of somatostatin receptors. The Journal of Clinical Endocrinology and Metabolism. ,vol. 65, pp. 1127- 1134 ,(1987) , 10.1210/JCEM-65-6-1127
L. VERSCHOOR, P. UITTERLINDEN, S. W. J. LAMBERTS, E. POZO, On the use of a new somatostatin analogue in the treatment of hypoglycaemia in patients with insulinoma. Clinical Endocrinology. ,vol. 25, pp. 555- 560 ,(1986) , 10.1111/J.1365-2265.1986.TB03609.X
STEVEN W. J. LAMBERTS, JEAN-CLAUDE REUBI, PIET UITERLINDEN, JOKE ZUIDERWIJK, PAUL VAN DEN WERFF, PETER VAN HAL, Studies on the mechanism of action of the inhibitory effect of the somatostatin analog SMS 201-995 on the growth of the prolactin/adrenocorticotropin-secreting pituitary tumor 7315a. Endocrinology. ,vol. 118, pp. 2188- 2194 ,(1986) , 10.1210/ENDO-118-6-2188
G.J. BRUINING, A.N BOSSCHAART, R.S.R. AARSEN, S.W.J. LAMBERTS, P.J.J. SAUER, E. DEL POZO, Normalization of glucose homeostasis by a long-acting somatostatin analog SMS 201-995 in a newborn with nesidioblastosis. European Journal of Endocrinology. ,vol. 113, pp. 334- ,(1986) , 10.1530/ACTA.0.112S334
S.E. Christensen, AaP. Hansen, K. Lundbæk, H. Ørskov, K. Seyer-Hansen, SOMATOSTATIN AND INSULINOMA The Lancet. ,vol. 305, pp. 1426- ,(1975) , 10.1016/S0140-6736(75)92640-9
J. C. Reubi, A somatostatin analogue inhibits chondrosarcoma and insulinoma tumour growth European Journal of Endocrinology. ,vol. 109, pp. 108- 114 ,(1985) , 10.1530/ACTA.0.1090108
K.G.M.M. Alberti, N. Juel Christensen, S. Engkjær Christensen, AA. Prange Hansen, J. Iversen, K. Lundbæk, K. Seyer-Hansen, H. Ørskov, INHIBITION OF INSULIN SECRETION BY SOMATOSTATIN The Lancet. ,vol. 302, pp. 1299- 1301 ,(1973) , 10.1016/S0140-6736(73)92873-0